As complex as reverse-payment antitrust lawsuits can be, the one being litigated against generic drug maker Ranbaxy over its settlement with Cephalon can be broken down to the difference between fine and coarse salt, said one of the attorneys bringing the case.
Foley & Lardner attorney James Matthews, who is representing fellow generic drug maker Apotex, told the jury set to preside over Apotex v. Cephalon that the name-brand drugmaker Cephalon essentially bought coarse kosher salt and then told the US patent office that it invented the finer version of the same substance.
“They didn’t even grind it. They just bought it. They went to the store and bought Morton fine salt and they told the patent office they made it,” Matthews said. He went on to explain that Ranbaxy later discovered the misconduct and then used it to obtain an anti-competitive settlement agreement with Cephalon for more than $26 million that delayed other generic companies from entering the market for six years. “Did they do it because they were afraid of the patent, and they thought they were going to lose the case? Or did they do it because they wanted the $26 million?”
What Matthews was likening to salt was modafinil, the active ingredient in Provigil, which Cephalon bought from a French company. What Cephalon eventually patented was “small particle modafinil.”
Full Content: Delaware Law Weekly
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
T-Mobile’s Acquisition of Ka’ena Corporation Receives FCC Approval
Apr 26, 2024 by
CPI
UK Regulator Announces Two New Senior Executive Appointments
Apr 26, 2024 by
CPI
Paramount Global and Skydance Media Near Merger Deal, Eyeing CEO Change
Apr 26, 2024 by
CPI
BHP Unveils £31bn Mining Megamerger Proposal with Anglo American
Apr 25, 2024 by
nhoch@pymnts.com
ByteDance Prefers Shutdown Over Sale of TikTok Amid US Ban Threats
Apr 25, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI